Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
119
Recruiting Now
119
Top Conditions in Phase 2 / Phase 3
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07252778 Phase 2, Phase 3
Recruiting
Effect of a Short-term Multi-strain Probiotic Supplementation in Endurance Athle...
Condition
Sports Nutrition
Enrollment
30 pts
Location
Poland
Sponsor
Krzysztof Durkalec-Michalski
NCT05892510 Phase 2, Phase 3
Recruiting
Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrie...
Condition
Ischemic Stroke, Acute
Enrollment
462 pts
Location
Australia, New Zealand
Sponsor
University of Melbourne
NCT07725562 Phase 2, Phase 3
Recruiting
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
Condition
Parkinson Disease (PD)
Enrollment
152 pts
Location
China
Sponsor
Zhejiang Vimgreen Pharmaceutic
NCT07075718 Phase 2, Phase 3
Recruiting
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generati...
Condition
Glaucoma
Enrollment
610 pts
Location
United States
Sponsor
Glaukos Corporation
NCT05413122 Phase 2, Phase 3
Recruiting
Evaluating Smoking Cessation Interventions for PWH in South Africa
Condition
Smoking Cessation
Enrollment
660 pts
Location
South Africa
Sponsor
Johns Hopkins University
NCT06333041 Phase 2, Phase 3
Recruiting
Study of Cannabidiol in Sanfilippo Syndrome
Condition
Sanfilippo Syndrome
Enrollment
35 pts
Location
United States
Sponsor
Lundquist Institute for Biomed
NCT07688551 Phase 2, Phase 3
Recruiting
Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation
Condition
Aphasia
Enrollment
130 pts
Location
United States
Sponsor
University of South Carolina
NCT06719193 Phase 2, Phase 3
Recruiting
DeMONSTRATE-TB Study in Ethiopia
Condition
Reducing Tuberculosis Incidence
Enrollment
131,438 pts
Location
Ethiopia
Sponsor
Management Sciences for Health
NCT07594314 Phase 2, Phase 3
Recruiting
Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute A...
Condition
Acute Ischemic Stroke
Enrollment
860 pts
Location
China
Sponsor
Xiang Luo
NCT06653348 Phase 2, Phase 3
Recruiting
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Condition
Ischemic Stroke
Enrollment
100 pts
Location
Iran
Sponsor
Mazandaran University of Medic
NCT06111638 Phase 2, Phase 3
Recruiting
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Condition
Hemophilia A
Enrollment
55 pts
Location
China
Sponsor
Shanghai Xinzhi BioMed Co., Lt
NCT05686538 Phase 2, Phase 3
Recruiting
Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplanta...
Condition
AML/MDS
Enrollment
80 pts
Location
Denmark
Sponsor
Rigshospitalet, Denmark
NCT07184684 Phase 2, Phase 3
Recruiting
Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS).
Condition
Chronic Rhinosinusitis Without Nasal Polyps
Enrollment
50 pts
Location
Sweden
Sponsor
Region Skane
NCT07737704 Phase 2, Phase 3
Recruiting
Assessment of a New Enhanced Xenograft in Open Maxillary Sinus Augmentation
Condition
Maxillary Sinus Floor Augmentation
Enrollment
30 pts
Location
Egypt
Sponsor
Misr International University
NCT07284784 Phase 2, Phase 3
Recruiting
A Study of Buntanetap in Participants With PD
Condition
Parkinson's Disease (PD)
Enrollment
500 pts
Location
United States
Sponsor
Annovis Bio Inc.
NCT06154252 Phase 2, Phase 3
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-...
Condition
Idiopathic Inflammatory Myopathy
Enrollment
74 pts
Location
United States, United Kingdom
Sponsor
Cabaletta Bio
NCT07084662 Phase 2, Phase 3
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffu...
Condition
Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment
80 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07502118 Phase 2, Phase 3
Recruiting
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (...
Condition
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment
40 pts
Location
Turkey (Türkiye)
Sponsor
Health Institutes of Turkey
NCT07185594 Phase 2, Phase 3
Recruiting
A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surg...
Condition
Postoperative Analgesia
Enrollment
360 pts
Location
China
Sponsor
Shandong Suncadia Medicine Co.
NCT06191965 Phase 2, Phase 3
Recruiting
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunct...
Condition
Schizophrenia and Related Disorders
Enrollment
100 pts
Location
United States, Switzerland
Sponsor
Mclean Hospital
NCT07426055 Phase 2, Phase 3
Recruiting
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Stage...
Condition
Prostate Cancer (Adenocarcinoma)
Enrollment
1,000 pts
Location
Poland
Sponsor
Affidea Nu-med Center of Oncol
NCT07159841 Phase 2, Phase 3
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-C...
Condition
Congenital Adrenal Hyperplasia
Enrollment
153 pts
Location
United States, Argentina, Australia
Sponsor
Crinetics Pharmaceuticals Inc.
NCT07738523 Phase 2, Phase 3
Recruiting
Caffeine Consumption and Rate Control in Permanent Atrial FIBrillation: The CAFI...
Condition
Atrial Fibrillation (AF)
Enrollment
50 pts
Location
Spain
Sponsor
Hospital Universitario Getafe
NCT07202078 Phase 2, Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Start...
Condition
Myeloma
Enrollment
900 pts
Location
Australia
Sponsor
Monash University
NCT06856525 Phase 2, Phase 3
Recruiting
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Condition
Electronic Cigarette Related Lung Damage
Enrollment
80 pts
Location
United States
Sponsor
Y. Michael Shim, MD
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology